Literature DB >> 16757358

A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro.

Kevin M O'Hayer1, Christopher M Counter.   

Abstract

Transgenic mice, cultured murine cells, and human cancer cell lines have widely been used to study Ras oncogenesis. Although extremely valuable systems, they could not be used to study Ras function in genetically defined human cells. In this regard, Ras is required for tumor formation in normal human somatic cells expressing SV-40 T/t antigens, which inactivate the tumor suppressors p53 and Rb and activate the oncogene c-Myc, and hTERT, the catalytic subunit of telomerase. Such a system allows not only the general requirements of Ras to be dissected in matched cells from different organisms or tissues but also the individual pathways required for tumor growth to be defined in human cells. This review will detail the methods of creating stable T/t Ag, TERT, Ras-expressing cell lines, as well as commonly used techniques of soft agar and xenograft tumor formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757358     DOI: 10.1016/S0076-6879(05)07050-3

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  32 in total

1.  cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis.

Authors:  Mark J Vignola; David F Kashatus; Gregory A Taylor; Christopher M Counter; Raphael H Valdivia
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Authors:  Zachary C Hartman; Junping Wei; Takuya Osada; Oliver Glass; Gangjun Lei; Xiao-Yi Yang; Sharon Peplinski; Dong-Wan Kim; Wenle Xia; Neil Spector; Jeffrey Marks; William Barry; Amy Hobeika; Gayathri Devi; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2.

Authors:  Brian D Freibaum; Christopher M Counter
Journal:  J Biol Chem       Date:  2008-07-01       Impact factor: 5.157

4.  Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Authors:  Kian-Huat Lim; Donita C Brady; David F Kashatus; Brooke B Ancrile; Channing J Der; Adrienne D Cox; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2009-11-09       Impact factor: 4.272

5.  Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.

Authors:  Daoxiang Zhang; Lin Li; Hongmei Jiang; Brett L Knolhoff; Albert C Lockhart; Andrea Wang-Gillam; David G DeNardo; Marianna B Ruzinova; Kian-Huat Lim
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

6.  The Chlamydia protease CPAF regulates host and bacterial proteins to maintain pathogen vacuole integrity and promote virulence.

Authors:  Ine Jorgensen; Maria M Bednar; Vishar Amin; Beckley K Davis; Jenny P Y Ting; Dewey G McCafferty; Raphael H Valdivia
Journal:  Cell Host Microbe       Date:  2011-07-21       Impact factor: 21.023

7.  Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma.

Authors:  Brian L Teng; Kathryn E Hacker; Shufen Chen; Anthony R Means; W Kimryn Rathmell
Journal:  Mol Oncol       Date:  2011-06-28       Impact factor: 6.603

8.  Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.

Authors:  Sameer H Issaq; Kian-Huat Lim; Christopher M Counter
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

9.  Rare codons capacitate Kras-driven de novo tumorigenesis.

Authors:  Nicole L K Pershing; Benjamin L Lampson; Jason A Belsky; Erin Kaltenbrun; David M MacAlpine; Christopher M Counter
Journal:  J Clin Invest       Date:  2014-12-01       Impact factor: 14.808

10.  Tumour maintenance is mediated by eNOS.

Authors:  Kian-Huat Lim; Brooke B Ancrile; David F Kashatus; Christopher M Counter
Journal:  Nature       Date:  2008-03-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.